^
    Back
    Association details:
    Biomarker:MAP2K1 K57T
    Cancer:Colorectal Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Vectibix (panitumumab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Cancer Discov
    Title:

    Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

    Excerpt:
    Biopsy of a patient's progressing liver metastasis following prolonged response to cetuximab revealed a MEK1(K57T) mutation as a novel mechanism of acquired resistance. This lesion regressed upon treatment with panitumumab and the MEK inhibitor trametinib.
    DOI:
    10.1158/2159-8290.CD-15-1283